MARKET

BLUE

BLUE

bluebird bio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

83.96
+0.84
+1.01%
After Hours: 84.00 +0.04 +0.05% 18:49 01/28 EST
OPEN
83.97
PREV CLOSE
83.12
HIGH
85.74
LOW
83.43
VOLUME
723.22K
TURNOVER
--
52 WEEK HIGH
163.43
52 WEEK LOW
71.42
MARKET CAP
4.64B
P/E (TTM)
-6.4634
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of BLUE and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 21 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

BLUE News

  • Acceleron stock soars on lung drug trial data
  • American City Business Journals.20h ago
  • IPO Update: Beam Therapeutics Proposes IPO Terms
  • Seeking Alpha - Article.1d ago
  • UPDATE 1-Novartis, GBT sickle cell drugs too expensive, draft U.S. report says
  • Reuters.4d ago
  • FDA Puts GlaxoSmithKline's Blood Cancer Drug In the Fast Lane
  • MotleyFool.com.01/21 20:15

More

Industry

Biotechnology & Medical Research
+0.97%
Pharmaceuticals & Medical Research
+0.58%

Hot Stocks

Name
Price
%Change

About BLUE

bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company's clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD). Its programs in oncology focuses on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. bb2121, its lead product candidate in oncology, is a CAR T cell product candidate for the treatment of multiple myeloma. It also has discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.
More

Webull offers bluebird bio Inc (BLUE) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.